NCT01690260

Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment

Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Northern Orthopaedic Division, Denmark · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Results of growth factors indicate that Bone Morphogenetic Proteins (BMP) have an exceptional ability to stimulate different characteristics of mesenchymale cells to osseous cells. Local application of BMP results in an increase of osseous tissue regardless of the location of the growth factor. 5 years clinical studies show that BMP's can stimulate an increase of osseous tissue and improve clinical results when autologous bone graft is reduced or removed. The purpose of this study is to examine whether recombinant growth factor BMP-2 can replace autologous bone graft in order to stimulating ossification during transplantation of osseous tissue.

Conditions

• Bone Degenerative Changes
• Osteoarthritis
• Degenerative Disorder of Bone

Interventions

Type	Name	Description
DRUG	Bone Morphogenetic Protein 2	12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
PROCEDURE	Autologous bone graft	Autologous bone graft in connection with bone docking operation.

Timeline

• Start date: 2004-09-01
• Primary completion: 2017-10-02
• Completion: 2017-10-02
• First posted: 2012-09-21
• Last updated: 2017-10-05

Locations

1 site across 1 country: Denmark